CABA Earnings — Cabaletta Bio, Inc. Common Stock Post-ER Performance | BigEarnings
CABA — Cabaletta Bio, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$3.78
Market Cap$616.3M
P/E—
52W Range$1.26 – $4.23
Next Earnings2026-08-06
About Cabaletta Bio, Inc. Common Stock
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
